• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Awakn Life Sciences Corp (OP: AWKNF )

    0.0800 -0.0088 (-9.91%)
    Streaming Delayed Price Updated: 11:38 AM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 21,955
    Open 0.0800
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0888
    Today's Range 0.0800 - 0.0800
    52wk Range 0.0422 - 0.1877
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
    Awakn Life Sciences partners with the University of Nottingham to advance in vivo testing of its aminoindane therapy for PTSD, with results expected by late 2024. 
    Via Benzinga
    Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
    Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate research into addiction treatments. 
    Via Benzinga

    Performance

    YTD
    -27.60%
    -27.60%
    1 Month
    -11.11%
    -11.11%
    3 Month
    -20.56%
    -20.56%
    6 Month
    -55.56%
    -55.56%
    1 Year
    -50.56%
    -50.56%

    More News

    Read More
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
    Via Benzinga
    Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
    Via Benzinga
    Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
    Via Benzinga
    Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
    Via Benzinga
    Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
    Via Benzinga
    U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
    Via Benzinga
    Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
    Via Benzinga
    Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
    Via Benzinga
    Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
    Via Benzinga
    Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
    Via Benzinga
    Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
    Via Benzinga
    Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
    Via Benzinga
    Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
    Via Benzinga
    Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
    Via Benzinga
    Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
    Via Benzinga
    Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
    Via Benzinga
    Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
    Via Benzinga
    Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
    Via Benzinga
    Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
    Via Benzinga
    EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.